Uristat launch brings J&J into OTC urinary pain analgesic market.
This article was originally published in The Tan Sheet
Executive Summary
J&J ENTERS OTC URINARY TRACT PAIN RELIEF CATEGORY with the marketing launch of Uristat during the week of June 18. Marketed by J&J's Advanced Care Products, the phenazopyridine hydrochloride 95 mg analgesic is indicated for the temporary relief of pain and discomfort associated with urinary tract infections. Uristat "relieves the pain but is not a cure," J&J said, stressing that "only a doctor can treat a UTI."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning